Search results
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
We always aim to provide a high standard of service to our community. If you are unhappy with any of our services it is important that you let us know.
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Did you join either of our Conferences this year? You can read about them inside this edition of Look Forward. We’ve had some fantastic feedback from our delegates so if you weren’t able to attend, you can watch or listen to the recordings from the day on our website.
Tuesday 28 July 2026, 7.00pm - 8.00pm - via Zoom - Please come and join Perm & Danielle for their latest meet up where we are delighted to welcome our inspirational guest speaker Emma Jayne Basudev who will be talking to us about mindfulness.
The latest research news from Retina UK.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
During RP awareness month, Paul Bacon has shared how his diagnosis has impacted his life and shared messages about how non visually impaired people can support those living with inherited sight loss. To learn more about inherited sight loss please take the time to read Paul's story.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
